 Today, Cytokinetics Incorporated NASDAQ: CYTK reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and statistically significant reductions in the average resting left ventricular outflow tract pressure gradient LVOT-G and the average post-Valsalva LVOT-G when compared to placebo. Why It Matters: The new data is a needed win for the Company after Astellas Pharma Inc OTC: ALPMY and Amgen Inc NASDAQ: AMGN have dropped partnerships with the Company this year. 